"Significant shift" as NICE widens prostate cancer drug use

NICE has changed unpopular guidance on abiraterone for hormone-sensitive prostate cancer after the entry of generics into the UK market.

J&J gets restricted label for PARP drug Akeega in EU

Drug is backed for BRCA+ prostate cancer patients only, a narrower group than rival Lynparza.

NICE's second Zytiga rejection 'shows need for flexible pric...

NICE has stuck with its original decision to reject NHS funding for Johnson & Johnson's Zytiga as a treatment for men with newly diagnosed advanced prostate cancer, drawing criticism fr

EMA starts review of Xtandi in hormone-sensitive prostate ca...

J&J warns generics will bite its pharma unit in the second h...

J&J ends 2018 on a high, but coming year looks shaky

Johnson & Johnson (J&J) has kicked off results season with a downbeat forecast for the year as competition to some of its top products starts to have an impact on revenues.